Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 3/2015

01.03.2015 | Retinal Disorders

A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada Disease

verfasst von: Eun Kyoung Lee, Sang-Yoon Lee, Hyeong Gon Yu

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

To develop a grading system for sunset glow fundus (SGF) based on the results of ultra-wide field retinal imaging and to investigate the factors related to the severity of SGF in patients with Vogt-Koyanagi-Harada (VKH) disease.

Methods

Records of 55 eyes with VKH disease were retrospectively reviewed. All patients had undergone serial fundus photography, ultra-wide field retinal imaging and spectral-domain optical coherence tomography. The morphologic characteristics of SGF and associated features related to the severity of the condition were evaluated.

Results

Sunset glow fundi were classified into 3 groups based on the extent and severity of depigmentary changes: early (n = 7), intermediate (n = 10) and advanced (n = 20). Grade 0 indicates the absence of sunset glow appearance. Eyes with a higher SGF grade were more likely to exhibit chronic recurrence (P < 0.001) and an anterior chamber reaction ≥ 2+ (P < 0.001), and were less likely to exhibit exudative retinal detachment (P < 0.001) at the initial presentation. Higher grades were more likely to exhibit cataracts (P < 0.001), glaucoma (P = 0.010), patchy chorioretinal atrophic lesions (P = 0.012), depigmented atrophic lesions (P < 0.001), an increased peripapillary atrophy/disc area ratio (P < 0.001), a decreased subfoveal choroidal thickness (P < 0.001), more frequent uveitis recurrences (P = 0.012) and a longer disease duration (P < 0.001). SGF progression was faster in eyes with a longer active inflammatory period.

Conclusions

We present a simple and logical grading system for SGF as determined by using ultra-wide field retinal imaging. This grading system offers a means of assessing the degree of inflammation and facilitates speculation about the duration of VKH disease.
Literatur
1.
Zurück zum Zitat Yamaki K, Hara K, Sakuragi S (2005) Application of revised diagnostic criteria for vogt-koyanagi-harada disease in Japanese patients. Jpn J Ophthalmol 49(2):143–148CrossRefPubMed Yamaki K, Hara K, Sakuragi S (2005) Application of revised diagnostic criteria for vogt-koyanagi-harada disease in Japanese patients. Jpn J Ophthalmol 49(2):143–148CrossRefPubMed
2.
Zurück zum Zitat Kitamura M, Takami K, Kitaichi N, Namba K, Kitamei H, Kotake S, Ohno S (2005) Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada’s disease. Am J Ophthalmol 139(6):1080–1085CrossRefPubMed Kitamura M, Takami K, Kitaichi N, Namba K, Kitamei H, Kotake S, Ohno S (2005) Comparative study of two sets of criteria for the diagnosis of Vogt-Koyanagi-Harada’s disease. Am J Ophthalmol 139(6):1080–1085CrossRefPubMed
3.
Zurück zum Zitat Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39(4):265–292CrossRefPubMed Moorthy RS, Inomata H, Rao NA (1995) Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39(4):265–292CrossRefPubMed
4.
Zurück zum Zitat Keino H, Goto H, Usui M (2002) Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol 240(10):878–882CrossRefPubMed Keino H, Goto H, Usui M (2002) Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation. Graefes Arch Clin Exp Ophthalmol 240(10):878–882CrossRefPubMed
5.
Zurück zum Zitat Rao NA, Gupta A, Dustin L, Chee SP, Okada AA, Khairallah M, Bodaghi B, Lehoang P, Accorinti M, Mochizuki M, Prabriputaloong T, Read RW (2010) Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology 117(3):591–599CrossRefPubMedCentralPubMed Rao NA, Gupta A, Dustin L, Chee SP, Okada AA, Khairallah M, Bodaghi B, Lehoang P, Accorinti M, Mochizuki M, Prabriputaloong T, Read RW (2010) Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease. Ophthalmology 117(3):591–599CrossRefPubMedCentralPubMed
6.
Zurück zum Zitat Keino H, Goto H, Mori H, Iwasaki T, Usui M (2006) Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 141(6):1140–1142CrossRefPubMed Keino H, Goto H, Mori H, Iwasaki T, Usui M (2006) Association between severity of inflammation in CNS and development of sunset glow fundus in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 141(6):1140–1142CrossRefPubMed
7.
Zurück zum Zitat Takahashi H, Takase H, Ishizuka A, Miyanaga M, Kawaguchi T, Ohno-Matsui K, Mochizuki M (2013) Choroidal Thickness in Convalescent Vogt-Koyanagi-Harada Disease. Retina 34(4):775–780 Takahashi H, Takase H, Ishizuka A, Miyanaga M, Kawaguchi T, Ohno-Matsui K, Mochizuki M (2013) Choroidal Thickness in Convalescent Vogt-Koyanagi-Harada Disease. Retina 34(4):775–780
8.
Zurück zum Zitat Kaines A, Tsui I, Sarraf D, Schwartz S (2009) The use of ultra wide field fluorescein angiography in evaluation and management of uveitis. Semin Ophthalmol 24(1):19–24CrossRefPubMed Kaines A, Tsui I, Sarraf D, Schwartz S (2009) The use of ultra wide field fluorescein angiography in evaluation and management of uveitis. Semin Ophthalmol 24(1):19–24CrossRefPubMed
9.
Zurück zum Zitat Manivannan A, Plskova J, Farrow A, McKay S, Sharp PF, Forrester JV (2005) Ultra-wide-field fluorescein angiography of the ocular fundus. Am J Ophthalmol 140(3):525–527CrossRefPubMed Manivannan A, Plskova J, Farrow A, McKay S, Sharp PF, Forrester JV (2005) Ultra-wide-field fluorescein angiography of the ocular fundus. Am J Ophthalmol 140(3):525–527CrossRefPubMed
10.
Zurück zum Zitat Leder HA, Campbell JP, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV, Nguyen QD (2013) Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect 3(1):30CrossRefPubMedCentralPubMed Leder HA, Campbell JP, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV, Nguyen QD (2013) Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect 3(1):30CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Campbell JP, Leder HA, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV, Nguyen QD (2012) Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol 154(5):908–911CrossRefPubMed Campbell JP, Leder HA, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, Do DV, Nguyen QD (2012) Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am J Ophthalmol 154(5):908–911CrossRefPubMed
12.
Zurück zum Zitat Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652CrossRefPubMed Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, Pivetti-Pezzi P, Tessler HH, Usui M (2001) Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652CrossRefPubMed
13.
Zurück zum Zitat Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ (1989) A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 107(12):1759–1766CrossRefPubMed Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ (1989) A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol 107(12):1759–1766CrossRefPubMed
14.
Zurück zum Zitat Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D (2013) Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91(6):e486–e493CrossRefPubMed Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D (2013) Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91(6):e486–e493CrossRefPubMed
15.
Zurück zum Zitat Jap A, Luu CD, Yeo I, Chee SP (2008) Correlation between peripapillary atrophy and corticosteroid therapy in patients with Vogt-Koyanagi-Harada disease. Eye (Lond) 22(2):240–245CrossRef Jap A, Luu CD, Yeo I, Chee SP (2008) Correlation between peripapillary atrophy and corticosteroid therapy in patients with Vogt-Koyanagi-Harada disease. Eye (Lond) 22(2):240–245CrossRef
16.
Zurück zum Zitat Guo YL, Du Y, He JF (2009) Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease. Am J Ophthalmol 947(5):946–947CrossRef Guo YL, Du Y, He JF (2009) Correlation between sunset glow fundus and initial dosage of corticosteroid in patients with Vogt-Koyanagi-Harada disease. Am J Ophthalmol 947(5):946–947CrossRef
17.
Zurück zum Zitat Inomata H, Rao NA (2001) Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131(5):607–614CrossRefPubMed Inomata H, Rao NA (2001) Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131(5):607–614CrossRefPubMed
18.
Zurück zum Zitat Rao NA, Wu GS (2000) Free radical mediated photoreceptor damage in uveitis. Prog Retin Eye Res 19(1):41–68CrossRefPubMed Rao NA, Wu GS (2000) Free radical mediated photoreceptor damage in uveitis. Prog Retin Eye Res 19(1):41–68CrossRefPubMed
19.
Zurück zum Zitat Suzuki S (1999) Quantitative evaluation of “sunset glow” fundus in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 43(4):327–333CrossRefPubMed Suzuki S (1999) Quantitative evaluation of “sunset glow” fundus in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 43(4):327–333CrossRefPubMed
Metadaten
Titel
A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada Disease
verfasst von
Eun Kyoung Lee
Sang-Yoon Lee
Hyeong Gon Yu
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 3/2015
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-014-2710-7

Weitere Artikel der Ausgabe 3/2015

Graefe's Archive for Clinical and Experimental Ophthalmology 3/2015 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.